Meningitis News and Research

Latest Meningitis News and Research

Sinovac second quarter sales increase 52.5% to $15.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2011.

12 Aug 2011

NanoLogix BNP and BNF Quick Test kits detect, identify Group B Strep in four to six hours

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today that the American Journal of Perinatology has published a peer-reviewed paper from the University of Texas Health Science Center - Houston confirming NanoLogix BioNanoPore (BNP) and BioNanoFilter (BNF) Quick Test technology detect and identify Group B Strep in four to six hours.

8 Aug 2011

Akonni to develop closed amplicon RT-PCR microarray for virus detection in CSF

Akonni Biosystems, a molecular diagnostics company that develops novel nucleic acid extraction and microarray-based testing systems designed to rapidly and economically analyze biological samples, today announced receipt of a $300K grant from the National Institutes of Health.

5 Aug 2011

Cubist initiates CXA-201 Phase 3 trial in complicated urinary tract infections

Cubist Pharmaceuticals, Inc. today announced the initiation of a pivotal Phase 3 trial of CXA-201 in patients with complicated urinary tract infections.

1 Aug 2011

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

Pfizer Inc today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company's supplemental Biologics License Application (sBLA) for use of Prevnar 13, in adults aged 50 and older.

30 Jul 2011

NIH selects Viamet's novel antifungal compound for inclusion in the TRND program

Viamet Pharmaceuticals, Inc. announced today that one of its novel antifungal compounds has been selected for inclusion in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program.

29 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

Financial Times examines product development partnerships developing drugs for neglected diseases

The Financial Times examines the rise of product development partnerships (PDPs), which are "non-governmental organizations that generate their own funding and build partnerships with universities, businesses, government and patients in low-income countries to develop new drugs, vaccines, prevention techniques and diagnostics for diseases such as tuberculosis, HIV, malaria, cholera and meningitis."

22 Jul 2011

NPR: Vaccine cost-benefit analysis complicates guidelines

The group that advises the U.S. government on vaccination thinks some new vaccines may not be worth the cost. In 2009, the Advisory Committee on Immunization Practices, or ACIP, decided it's not cost effective to routinely vaccinate boys for human papillomavirus, though they do recommend the vaccine for girls.

22 Jul 2011

Researchers closer to developing meningitis B vaccine

"New research may bring scientists one step closer to developing a vaccine that protects against hundreds of strains of meningococcus B, the most common cause of bacterial meningitis," according to research published last week in Science Translational Medicine, HealthDay News reports.

18 Jul 2011

Novel combined technique for treating neoplastic meningitis, hydrocephalus

Approximately five to ten percent of patients with primary or metastatic cancer suffer from devastating neurological complications such as headaches, seizures, confusion, difficulty swallowing and visual disturbances. These deficits are caused by a life-threatening form of brain invasion from cancer called neoplastic meningitis.

15 Jul 2011

Final Atlantis space trip may open new era of research into infectious diseases

On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.

7 Jul 2011

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

A powerful new class of therapeutics, known as recombinant attenuated Salmonella vaccines (RASV), holds great potential in the fight against fatal diseases including hepatitis B, tuberculosis, cholera, typhoid fever, AIDS and pneumonia.

30 Jun 2011

Copenhagen chemist reveals mechanism behind deadly infections

Anthrax, septicemia and meningitis are some of the planet's most deadly infections. In part because doctors lack basic insights to prevent and cure diseases caused by so called Gram-positive bacteria. Now, a chemist from the University of Copenhagen has revealed the mechanism behind these deadly infections.

24 Jun 2011

MA launches national campaign to raise awareness on meningitis

This Father's Day is a special day for Angels Dads on Meningitis (ADOM). Angel dads from across the country came together in Denver, Colorado to launch a national campaign on meningitis awareness.

20 Jun 2011

PEG hydrogel sealant effectively encloses surgical wounds after spinal procedures

A gel that creates a watertight seal to close surgical wounds provides a significant advance in the treatment of patients following spinal procedures, effectively sealing spinal wounds 100 percent of the time, a national multicenter randomized study led by researchers at UC Davis has found.

17 Jun 2011

Menafrivac more effective, less expensive than older meningitis vaccines, studies say

The meningococcal vaccine MenAfriVac, which is made by the Indian generic drug company Serum Institute, is "dramatically better" at producing a protective effect among African children in three countries than "older so-called meningococcal polysaccaride vaccines, including Mencevax from GlaxoSmithKline," according to a paper describing two studies published in the New England Journal of Medicine, Reuters reports.

17 Jun 2011

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France.

15 Jun 2011

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

New data from a pivotal study in more than 1,800 infants show that Novartis candidate vaccine Bexsero induces a robust immune response to meningococcal serogroup B when given alone or when co-administered with other routine vaccines.

15 Jun 2011

Meningitis News and Research

Latest Meningitis News and Research

Sinovac second quarter sales increase 52.5% to $15.7 million

NanoLogix BNP and BNF Quick Test kits detect, identify Group B Strep in four to six hours

Akonni to develop closed amplicon RT-PCR microarray for virus detection in CSF

Cubist initiates CXA-201 Phase 3 trial in complicated urinary tract infections

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

NIH selects Viamet's novel antifungal compound for inclusion in the TRND program

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Financial Times examines product development partnerships developing drugs for neglected diseases

NPR: Vaccine cost-benefit analysis complicates guidelines

Researchers closer to developing meningitis B vaccine

Novel combined technique for treating neoplastic meningitis, hydrocephalus

Final Atlantis space trip may open new era of research into infectious diseases

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

Copenhagen chemist reveals mechanism behind deadly infections

MA launches national campaign to raise awareness on meningitis

PEG hydrogel sealant effectively encloses surgical wounds after spinal procedures

Menafrivac more effective, less expensive than older meningitis vaccines, studies say

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Meningitis News and Research

Latest Meningitis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in